Health · 2 views
Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 2 Community interest
Brief read Under 1 min brief 27 words
Summary
(MedPage Today) -- Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13Continue reading
- The Ebola outbreak is breaking records -- and just marked a grim milestoneContinue reading
- Pathology research identifies potential new target for preventing brain metastasisContinue reading
- Certain Myasthenia Gravis Patients May Need More Time to Respond to EfgartigimodContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow